middle.news
AVITA Medical Accelerates Growth with New FDA Approvals and 30% Revenue Surge
8:05am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
AVITA Medical Accelerates Growth with New FDA Approvals and 30% Revenue Surge
8:05am on Monday 2nd of June, 2025 AEST
Key Points
Q4 2024 commercial revenue rose 30% to $18.4 million
Full-year 2024 revenue increased 29% to $64 million
FDA approvals granted for Cohealyx and RECELL GO mini in December 2024
Amended credit agreement with OrbiMed to ease revenue covenants through 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Avita Medical (ASX:AVH)
OPEN ARTICLE